On Oct 31, major Wall Street analysts update their ratings for $Penumbra (PEN.US)$, with price targets ranging from $232 to $248.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $180 to $248.
Needham analyst Michael Matson maintains with a hold rating.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $222 to $232.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and adjusts the target price from $225 to $235.
Truist Financial analyst Richard Newitter maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Penumbra (PEN.US)$'s main analysts recently are as follows:
Following the company's third-quarter earnings surpassing expectations, it's noted that the completion of the THUNDER trial enrollment and the FDA clearance of two new CAVT products, Lightning Bolt 6X and 12, position the company well for future growth. The potential for innovation in a market that has not been fully tapped is anticipated to fuel Penumbra's continued revenue growth in double digits and contribute to significant improvements in profit margins.
The firm expressed that the third quarter revenue and operating margin beat has bolstered confidence in meeting the revised full-year guidance for 2024 and the anticipated acceleration of growth in 2025, which they believe is crucial for the stock's upward trajectory.
Here are the latest investment ratings and price targets for $Penumbra (PEN.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$Penumbra (PEN.US)$的評級，目標價介於232美元至248美元。
貝雅分析師David Rescott維持買入評級，並將目標價從180美元上調至248美元。
Needham分析師Michael Matson維持持有評級。
加皇資本市場分析師Shagun Singh Chadha維持買入評級，並將目標價從222美元上調至232美元。
派傑投資分析師Matthew O'Brien維持買入評級，並將目標價從225美元上調至235美元。
儲億銀行分析師Richard Newitter維持買入評級。
此外，綜合報道，$Penumbra (PEN.US)$近期主要分析師觀點如下：
鑑於公司第三季度收入超出預期，注意到暴風試驗招募的完成以及FDA批准兩款新的CAVt產品，閃電箭6X和12，爲公司未來的增長奠定了良好基礎。在一個尚未完全開發的市場中創新的潛力有望推動penumbra的營業收入持續以兩位數增長，並有助於利潤率的顯著改善。
該公司表示，第三季度的營業收入和營業利潤率的超額增長增強了對2024年修訂的全年指引和預計在2025年增速的信心，他們認爲這對股票上升軌道至關重要。
以下爲今日5位分析師對$Penumbra (PEN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
